BIO Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.…
Industry Peers
Medical DevicesKey Statistics
About Bio-Rad Laboratories (NYSE: BIO)
›
Bio-Rad Laboratories (NYSE: BIO) is listed on the New York Stock Exchange, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 7,450 employees.
The shares were at 367.50 USD on 19 November 2026, up 17.4% over 52 weeks. Its 52-week range is 236.73 USD to 396.23 USD: the price is 7.3% below the high and 55.2% above the low.
At a market capitalisation of 9.88B USD, it trades at 9.8 times trailing earnings and 37.1 times forward earnings. The median trailing P/E of its 18 largest Medical Devices peers is 26.3, a discount of 63% for BIO.
Bio-Rad Laboratories reports return on equity of 10.2%, an operating margin of 9.5% and revenue up 0.5% year over year.
It holds more cash than debt, a net cash position of 300.90M USD. Its Piotroski F-score is 5 out of 9, an average reading of its financial health. 3 analysts cover the stock, with an average rating of Hold; their mean price target of 356.67 USD is 2.9% below the current price. The next earnings report is expected on 11 February 2027.